-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Daiichi Sankyo and AstraZeneca's curvature bead mono-deuxtecan have been recommended by the European Union for the treatment of non-removable or metastasis HER2-positive breast cancer patients who have received two or more therapies.
, about 520,000 cases of breast cancer are diagnosed each year, about one in five of which are HER2-positive.
of breast cancer is enormous, leading to more than 137,000 deaths each year.
after the application was reviewed under an accelerated assessment process, the Humane Medicines Board (CHMP) gave a positive opinion on the results of the key Phase II DESTINY-Breast01 trial, published in the New England Journal of Medicine.
in the TESTINY-Breast01 trial, the clinically significant long-lasting activity was demonstrated in patients treated with two or more anti-HER2 treatments.
Gilles Gallant, Senior Vice President, Global Head of Cancer Research and Development at Daiichi Sankyo, said, "We are encouraged by THEP's positive insights as the needs of HER2-positive metastassic breast cancer patients remain unsolved.
in the United States and Japan, tertojudan single anti-deruxtecan has been used in HER2-positive metastasis breast cancer patients."
。
